Sedana Medical AB (publ) (STO:SEDANA)

CTI BioPharma Income Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	196.12	178.75	153.87	122.87	159.15	141.77
Revenue Growth (YoY)	16.27%	16.17%	25.23%	-22.80%	12.26%	97.88%
Cost of Revenue	58.11	52.61	44.89	36.79	52.45	52.87
Gross Profit	138.02	126.14	108.98	86.07	106.71	88.9
Selling, General & Admin	157.43	156.6	154.74	169.94	148.31	102.42
Research & Development	20.51	20.29	20.81	19.94	19.7	7.86
Other Operating Expenses	0.03	0.03	-0.02	0.12	-0.11	-0.02
Operating Expenses	177.96	176.92	175.53	190.01	167.9	110.26
Operating Income	-39.95	-50.78	-66.55	-103.93	-61.2	-21.36
Interest Expense	-0.18	-0.18	-0.22	-0.26	-0.24	-0.19
Interest & Investment Income	16.49	16.49	15.17	3.58	-	-
Currency Exchange Gain (Loss)	23.08	24.52	-7.42	27.68	4.07	-2.56
Other Non Operating Income (Expenses)	-48.61	-0	-	-	-	-0
Pretax Income	-49.16	-9.95	-59.02	-72.93	-57.37	-24.1
Income Tax Expense	1.68	0.73	0.59	0.57	0.6	3.04
Net Income	-50.85	-10.67	-59.61	-73.51	-57.97	-27.14
Net Income to Common	-50.85	-10.67	-59.61	-73.51	-57.97	-27.14
Shares Outstanding (Basic)	99	99	99	99	93	92
Shares Outstanding (Diluted)	99	99	99	99	93	92
Shares Change (YoY)	-	-	-	6.85%	1.54%	9.27%
EPS (Basic)	-0.51	-0.11	-0.60	-0.74	-0.62	-0.30
EPS (Diluted)	-0.51	-0.11	-0.60	-0.74	-0.62	-0.30
Free Cash Flow	-31.57	-13.99	-38.58	-116.17	-46.41	-20.29
Free Cash Flow Per Share	-0.32	-0.14	-0.39	-1.17	-0.50	-0.22
Gross Margin	70.37%	70.57%	70.83%	70.06%	67.05%	62.71%
Operating Margin	-20.37%	-28.41%	-43.25%	-84.59%	-38.45%	-15.07%
Profit Margin	-25.93%	-5.97%	-38.74%	-59.83%	-36.42%	-19.14%
Free Cash Flow Margin	-16.10%	-7.82%	-25.07%	-94.55%	-29.16%	-14.31%
EBITDA	-37.95	-48.77	-64.19	-100.56	-56.8	-16.92
EBITDA Margin	-19.35%	-27.28%	-41.72%	-81.84%	-35.69%	-11.93%
D&A For EBITDA	2	2.01	2.36	3.38	4.4	4.44
EBIT	-39.95	-50.78	-66.55	-103.93	-61.2	-21.36
EBIT Margin	-20.37%	-28.41%	-43.25%	-84.59%	-38.45%	-15.07%

Updated Feb 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.